M. Bon

Abstract 1296: MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells

Jean-David Fumet, F. Ghiringhelli, S. Ladoire, 2022, Cancer Research.

Immunological features of coronavirus disease 2019 in patients with cancer

Jean-David Fumet, F. Ghiringhelli, E. Limagne, 2020, European Journal of Cancer.

First-line durvalumab and tremelimumab with chemotherapy in RAS-mutated metastatic colorectal cancer: a phase 1b/2 trial

R. Boidot, C. Borg, A. Bertaut, 2023, Nature Medicine.

MEK inhibition overcomes chemoimmunotherapy resistance by inducing CXCL10 in cancer cells.

Jean-David Fumet, L. Arnould, B. Collin, 2022, Cancer cell.